Attendee search 

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States. Helsinn’s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. Helsinn Group in-licenses early-to-late stage new chemical entities, completes their development through the performance of pre-clinical /clinical studies and Chemistry, Manufacturing, and Control (CMC) development, and files and attains their market approvals worldwide. Helsinn’s products are out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how whom Helsinn assists and supports by providing a full range of product and scientific management services, including commercial, regulatory financial, legal, and medical marketing advice. The active pharmaceutical ingredients and the finished products are manufactured according to the highest quality, safety, and environmental standards at Helsinn’s GMP facilities in Switzerland and Ireland and supplied worldwide to its customers. Further information on Helsinn Group is available at www.helsinn.com.

uniQure is a world-leading gene therapy company. Our lead product, Glybera, received a positive opinion from CHMP in July 2012 and is poised to become the first gene therapy approved in the Western World, capping more than 30 years research in this area.

This positive outcome validates uniQure's AAV platform and, most importantly, the only commercially scalable manufacturing system currently available anywhere.

uniQure's plug-and-play platform offers the opportunity to develop many additional therapies on a platform that is now validated and accepted as safe by regulatory authorities.

uniQure's second programme, for Hemophilia B ($1.5bn market) is in a Phase I/II clinical study and has shown up to 30 months stable, therapeutic expression from a single treatment (NEJM Dec 2011).

Over the coming 6 months further programmes for Porphyria, Parkinson's Disease and Sanfilippo B are expected to enter Phase I/II clinical trials.

uniQure is based in Amsterdam, and backed by Forbion, Gilde, Advent, CAPE and other investors. We would be interested in meeting to discuss potential collaborations and also potential investment opportunities.

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology.  The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies.  Astex Pharmaceuticals developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.

For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.

Immune Targeting Systems is an emerging leader in the development of vaccine products that work by promoting T-cell responses against viruses and cancers (“T-cell vaccines”). The company’s lead product Flunisyn™, currently in clinical development, is a novel T-cell vaccine which aims to elicit immune protection against multiple strains of influenza. The Company’s technology also supports a product portfolio which includes Hepsyn-B, an attractive therapeutic hepatitis B vaccine and T-cell vaccines against cancers.